Patient Burden of Nonsegmental Vitiligo: A US Real-World Survey of Dermatologists and Their Patients
ConclusionA high patient burden was reported by dermatologists and their patients with vitiligo who had  ≤ 10% affected body surface area, including psychosocial and psychological consequences. These findings highlight an unmet need in the treatment of vitiligo. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - May 16, 2024 Category: Dermatology Source Type: research

Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged  ≥ 2 Years with Mild to Moderate Atopic Dermatitis
ConclusionCrisaborole was effective and well tolerated in Chinese patients aged  ≥ 2 years with mild to moderate AD.Trial RegistrationClinicalTrials.gov, NCT04360187. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - May 15, 2024 Category: Dermatology Source Type: research

Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study —IL PSO (Italian Landscape Psoriasis)
ConclusionThis study supports the long-term effectiveness and safety of ixekizumab in a real-world setting. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - May 15, 2024 Category: Dermatology Source Type: research

Anti-aging Effects of Tirbanibulin 1% Ointment: A Real-Life Experience
ConclusionsTirbanibulin 1% ointment seems able to improve skin aging as a desirable side effect at the site of application for AKs on chronic photodamaged skin. Such preliminary observation needs further confirmation in real-life studies on larger cohorts of patients, to explain the pathogenic mechanisms responsible for such aesthetically relevant results. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - May 14, 2024 Category: Dermatology Source Type: research

Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials
ConclusionsHigher proportions of risankizumab-treated (vs placebo-treated) patients achieved enthesitis and/or dactylitis resolution and meaningful improvements in patient-reported outcomes at week 24 and generally sustained responses at week 52. Thus, risankizumab may result in sustained alleviation of PsA-related pathognomonic musculoskeletal lesions of enthesitis/dactylitis.Clinicaltrials.gov identifiersNCT03675308, and NCT03671148. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - May 13, 2024 Category: Dermatology Source Type: research

Effects of 15% Azelaic Acid Gel in the Management of Post-Inflammatory Erythema and Post-Inflammatory Hyperpigmentation in Acne Vulgaris
ConclusionThe results indicate that 15% AzA gel effectively improved acne-induced PIE and PIH with minimal adverse reactions, making it a viable clinical application. In the study population, it had no adverse effects on skin barrier function and contributed positively to acne improvement and patient quality of life.Trial RegistrationThis study was registered with the Chinese Clinical Trial Registry (ChiCTR.org.cn) under the identifier ChiCTR2300076959. The registration date was 25 October 2023, retrospectively registered. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - May 11, 2024 Category: Dermatology Source Type: research

Unmet Needs and Treatment Preference of Systemic Treatments for Moderate-to-Severe Psoriasis from the Perspectives of Patients and Dermatologists in China
ConclusionsUnmet needs of systemic treatments remain for msPsO in China. Once-daily oral treatment is preferred over biweekly subcutaneous injections to treat msPsO when other treatment attributes are comparable. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - May 11, 2024 Category: Dermatology Source Type: research

Comparison of the Efficacy of Clascoterone, Trifarotene, and Tazarotene for the Treatment of Acne: A Systematic Literature Review and Meta-Analysis
ConclusionNo significant differences in efficacy were observed between clascoterone, trifarotene, and tazarotene after 12  weeks of treatment in patients with moderate-to-severe acne. Differences in application frequency and safety profile should also be taken into consideration when making treatment decisions. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - May 11, 2024 Category: Dermatology Source Type: research

Effects of 15% Azelaic Acid Gel in the Management of Post-Inflammatory Erythema and Post-Inflammatory Hyperpigmentation in Acne Vulgaris
ConclusionThe results indicate that 15% AzA gel effectively improved acne-induced PIE and PIH with minimal adverse reactions, making it a viable clinical application. In the study population, it had no adverse effects on skin barrier function and contributed positively to acne improvement and patient quality of life.Trial RegistrationThis study was registered with the Chinese Clinical Trial Registry (ChiCTR.org.cn) under the identifier ChiCTR2300076959. The registration date was 25 October 2023, retrospectively registered. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - May 11, 2024 Category: Dermatology Source Type: research

Unmet Needs and Treatment Preference of Systemic Treatments for Moderate-to-Severe Psoriasis from the Perspectives of Patients and Dermatologists in China
ConclusionsUnmet needs of systemic treatments remain for msPsO in China. Once-daily oral treatment is preferred over biweekly subcutaneous injections to treat msPsO when other treatment attributes are comparable. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - May 11, 2024 Category: Dermatology Source Type: research

Comparison of the Efficacy of Clascoterone, Trifarotene, and Tazarotene for the Treatment of Acne: A Systematic Literature Review and Meta-Analysis
ConclusionNo significant differences in efficacy were observed between clascoterone, trifarotene, and tazarotene after 12  weeks of treatment in patients with moderate-to-severe acne. Differences in application frequency and safety profile should also be taken into consideration when making treatment decisions. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - May 11, 2024 Category: Dermatology Source Type: research

Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study
ConclusionsThese data demonstrated the durable, real-world effectiveness of RZB in patients with moderate-to-severe PsO through continued improvement in disease and symptom severity over 18  months, with most of the patients reporting clear/almost clear skin. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - May 10, 2024 Category: Dermatology Source Type: research

OPT-In; Optimized Patient Treatment Outcomes in Plaque Psoriasis: A 3-Year State-Transition Treatment-Sequencing Model in the Italian Setting
ConclusionsResults suggest that selecting the most effective treatment sequences for incident patients provides the greatest opportunity to reduce treatment failures and maximize patient outcomes with a modest impact on costs. While regional variations exist, there is room for improvement across the board, which could translate to more efficient local healthcare systems. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - May 10, 2024 Category: Dermatology Source Type: research

Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study
ConclusionsThese data demonstrated the durable, real-world effectiveness of RZB in patients with moderate-to-severe PsO through continued improvement in disease and symptom severity over 18  months, with most of the patients reporting clear/almost clear skin. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - May 10, 2024 Category: Dermatology Source Type: research